DGAP-News: SYGNIS AG / Key word(s): Product Launch
SYGNIS AG: SYGNIS presents its first own product line based on PrimPol
technology: TruePrime(TM) (news with additional features)
20.11.2014 / 08:00
---------------------------------------------------------------------
Press Release
SYGNIS presents its first own product line based on PrimPol technology:
TruePrime(TM)
- TruePrime(TM) revolutionizes whole genome and transcriptome
amplification
- First product will be developed for single cell DNA amplification
- Evaluation by an industry leading partner for use on own Next
Generation Sequencing (NGS) platform ongoing
- Product launch planned for January 2015
Madrid, Spain and Heidelberg, Germany, November 20th, 2014 - SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the
inaugural launch of its first new product line TruePrime(TM).
TruePrime(TM) is the brand name of a series of kits dedicated to the
amplification of various DNA or RNA species for a multitude of
applications. TruePrime(TM) stands for a revolutionary change in the way
DNA or RNA is amplified. While the current gold standard MDA (multiple
displacement amplification) needs short pieces of DNA ("oligonucleotides")
to start off the amplification, TruePrime(TM) does not need any synthetic
random primers. TruePrime(TM) is based on a combination of SYGNIS' recently
discovered polymerase TthPrimPol and Phi29 DNA polymerase. In this set up,
TthPrimPol synthesizes the primers needed for Phi29 DNA pol on the fly,
which allows for the amplification of genomic DNAs.
The key advantages of the TruePrime(TM) product line include complete
absence of common artifacts linked to the use of oligonucleotides, a
reduced amplification bias compared to methods using random synthetic
primers and an exquisite reproducibility when DNA is amplified from single
mammalian cells. Moreover, TruePrime(TM) shows superior sensitivity, is
easy to use and works perfectly well with all commonly used NGS platforms
such as Illumina and IonTorrent. The Company plans to launch the first kit
for DNA amplification from single cells in January of 2015.
Single cell analysis has been named "Method of the year" by the renowned
journal "Nature Methods" and today is one of the most exciting but also one
of the most challenging applications of NGS. The features of TruePrime(TM)
make this product highly attractive for this type of analyses especially in
life science areas such as human genetics, oncology, or pathology where
researchers need to obtain biological information from the smallest sample
amounts.
"We are very proud and excited about the development of our first kit from
our newly introduced TruePrime(TM) product line. With this product line,
based on our proprietary PrimPol technology, we are addressing key
challenges in NGS as well as in other downstream applications, where DNA
analysis is limited due to small amounts of available sample material down
to single cells," Pilar de la Huerta, CEO and CFO of SYGNIS commented. "In
addition, we are driving adoption of NGS into more commercial applications
by providing solutions which are compatible with major NGS platforms and
support standardization of workflows. Given the superiority of
TruePrime(TM) over all technologies for whole genome DNA amplification
available today, SYGNIS is convinced it will benefit from future growth
rates and gain a significant portion of the market."
SYGNIS is currently developing a series of TruePrime(TM) kits that are
expected to be launched throughout 2015 and 2016 to bring the benefits of
this new technology to researchers working on a variety of applications.
Starting January 2015, the kits will be available via SYGNIS' own sales
channels and through regional and international life science distributors.
In addition, SYGNIS is planning to also expand the market for its new
products through OEM agreements with international market leading
companies.
SYGNIS has cloned, characterized, and patented a PrimPol thermostable
version, TthPrimPol, following the seminal characterization of human
PrimPol by one of SYGNIS' scientific fathers, Prof. Luis Blanco, at the end
of 2013. On November 12th, Prof. Blanco was granted with the renowned
Carmen and Severo Ochoa Prize 2014 by the Carmen and Severo Ochoa
Foundation from the Spanish National Research Council (CSIC), which
recognizes the work of excellent scientists in the field of molecular
biology in Spain. This brand new amplification technology is
patent-protected by SYGNIS until 2033.
About PrimPol
PrimPol is one of the most innovative discoveries in the molecular biology
field and one of the key products in SYGNIS' portfolio. Key features of
this enzyme family are the duality as a RNA primase and DNA polymerase, and
its high tolerance to damaged DNA. The primase function of PrimPol allows
it to start reading and copying DNA without the need for providing primers,
as required by all other commercially available polymerases. Using random
primers can bias the amplification and sequencing results. The polymerase
function of PrimPol displays a highly specific activity, being very
efficient also when copying DNA with different lesions.
About the Next Generation Sequencing market
Today, NGS is seen as the fastest-growing and most lucrative segment in the
genomics market with an estimated annual growth rate of more than 23% in
the years to come. The global NGS market volume today is worth $2.5 billion
and is poised to reach $8.7 billion by 2020 (MarketsandMarkets, September
2014). While still mostly used in research institutions, ongoing
developments for higher throughput, increased accuracy, and cost efficiency
as well as value creating data management will make NGS more and more
attractive for commercial applications such as diagnostics, drug discovery,
biomarker discovery as well as personalized medicine in clinical
laboratories, hospitals and in pharma companies.
For further information please contact:
<pre>
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.es
</pre>
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the
development and commercialization of products for DNA amplification and
sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard
segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for
whole genome DNA amplification, SensiPhi(R), licensed to an industry
leading partner and is currently developing its own TruePrime(TM) product
line based on its proprietary PrimPol technology for use in the fast
growing field of Next Generation Sequencing. The first product for single
cell DNA amplification is expected to be launched in January 2015.
### Disclaimer
This publication is intended for information only and constitutes neither
an offer to sell nor an invitation to buy securities. Some statements
included in this press release, relating neither to proven financial
results nor other historical data, should be viewed as forward-looking,
i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered
to be total guarantees since given their very nature they are subject to
known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of
SYGNIS AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to
publicly update or revise these statements in the light of new information
or future results or for any other reason.###
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=XOSJPHEPOJ
Document title: SYGNIS 141120_PR TruePrime_EN
---------------------------------------------------------------------
20.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: SYGNIS AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: 06221 454-6
Fax: 06221 454-700
E-mail: contact@sygnis.de
Internet: www.sygnis.de
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
298114 20.11.2014
DGAP-News: SYGNIS AG: SYGNIS presents its first own product line based on PrimPol technology: TruePrime(TM) (news with additional features)
| Source: EQS Group AG